In this issue of Blood, Herman et al elucidate the in vivo effects of ibrutinib (a BTK inhibitor) in various disease compartments of patients with chronic lymphocytic leukemia (CLL).
|Original language||English (US)|
|Number of pages||2|
|State||Published - May 22 2014|
ASJC Scopus subject areas
- Cell Biology